US 12,017,979 B2
Molecules
Ian Holmes, Melbourne (AU); Weiguang Zeng, Melbourne (AU); David Jackson, Melbourne (AU); Christophe Demaison, Melbourne (AU); and Grant McLachlan, Melbourne (AU)
Assigned to ENA Respiratory Pty Ltd, Sydney (AU)
Filed by ENA Respiratory Pty Ltd, Sydney (AU)
Filed on Mar. 23, 2023, as Appl. No. 18/112,091.
Application 18/112,091 is a continuation of application No. 17/622,451, previously published as PCT/AU2020/050660, filed on Jun. 26, 2020.
Claims priority of application No. 2019902231 (AU), filed on Jun. 26, 2019; and application No. 2019904862 (AU), filed on Dec. 20, 2019.
Prior Publication US 2023/0257345 A1, Aug. 17, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 321/14 (2006.01); A61K 47/60 (2017.01); A61K 47/64 (2017.01); A61P 31/12 (2006.01); C08G 65/334 (2006.01)
CPC C07C 321/14 (2013.01) [A61K 47/60 (2017.08); A61K 47/64 (2017.08); A61P 31/12 (2018.01); C08G 65/3348 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A compound, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is:

OG Complex Work Unit Chemistry